NPHC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NPHC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Nutra Pharma's total inventories for the quarter that ended in Sep. 2022 was $0.05 Mil. Nutra Pharma's average total inventories from the quarter that ended in Jun. 2022 to the quarter that ended in Sep. 2022 was $0.05 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Nutra Pharma's Net-Net Working Capital per share for the quarter that ended in Sep. 2022 was $-0.00.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Nutra Pharma's Days Inventory for the three months ended in Sep. 2022 was 101.27.
Inventory Turnover measures how fast the company turns over its inventory within a year. Nutra Pharma's Inventory Turnover for the quarter that ended in Sep. 2022 was 0.90.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Nutra Pharma's Inventory-to-Revenue for the quarter that ended in Sep. 2022 was 0.42.
The historical data trend for Nutra Pharma's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nutra Pharma Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Total Inventories | Get a 7-Day Free Trial | 0.02 | 0.04 | 0.01 | 0.01 | 0.03 |
Nutra Pharma Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Total Inventories | Get a 7-Day Free Trial | 0.03 | 0.03 | 0.06 | 0.04 | 0.05 |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Nutra Pharma (OTCPK:NPHC) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Nutra Pharma's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2022 is
Net-Net Working Capital Per Share (Q: Sep. 2022 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (0 | + | 0.75 * 0.022 | + | 0.5 * 0.049 | - | 16.3 |
- | 0.012 | - | 0) | / | 7596.85 | ||
= | -0.00 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Nutra Pharma's Days Inventory for the three months ended in Sep. 2022 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Sep. 2022 ) | / | Cost of Goods Sold (Q: Sep. 2022 ) | * | Days in Period |
= | 0.0455 | / | 0.041 | * | 365 / 4 | |
= | 101.27 |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
Nutra Pharma's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Sep. 2022 ) | / | Average Total Inventories (Q: Sep. 2022 ) |
= | 0.041 | / | 0.0455 | |
= | 0.90 |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Nutra Pharma's Inventory to Revenue for the quarter that ended in Sep. 2022 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Sep. 2022 ) | / | Revenue (Q: Sep. 2022 ) |
= | 0.0455 | / | 0.109 | |
= | 0.42 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of Nutra Pharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Rik J Deitsch | officer: Chief Executive Officer | 4001 NW 73 WAY, CORAL SPRINGS FL 33065 |
Dan Oran | director | 8411 W OAKLAND PARK BLVD, #201, SUNRISE FL 33351 |
Bruno Sartori | other: Former CFO | 275 COMMERCIAL BLVD, STE 260, FT LAUDERDALE FL 33308 |
Harold Henry Rumph | director, officer: President - ReceptoPharm | 1537 N.W. 65TH AVENUE, PLANTATION FL 33313 |
David Michael Isserman | officer: Chief Marketing Officer | 2776 UNIVERSITY DRIVE, CORAL SPRINGS FL 33065 |
Garry Pottruck | director | 10768 NW 18TH CT, CORAL SPRINGS FL 33071 |
Paul F Reid | director | 9610 NW 24 CT, SUNRISE FL 33322 |
Michael Doherty | director, officer: Executive Chairman | |
Tanvir A Khandaker | director | 387 PARK AVENUE SOUTH THIRD FLOOR, NEW YORK NY 10016 |
Stewart Alan Lonky | director | 1158 CHAUTAUQUA BLVD., PACIFIC PALISADES CA 90272 |
Stanley Jack Cherelstein | director | 2401 SW MANOR HILL DRIVE, PALM CITY FL 34990 |
Michael Flax | director, officer: Chief Financial Officer | 2499 BANYAN RD, BOCA RATON FL 33432 |
Mcclelland David C Sr | director | P.O. BOX 263, FINDLEY LAKE NY 14736 |
Mitchell S Felder | director | PO BOX 1332, HERMITAGE PA 16148 |
Khalsa Soram Singh Md | director | 436 N BEDFORD DR, BEVERLY HILLS CA 90210 |
From GuruFocus
By Marketwired Marketwired • 04-19-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.